Becton, Dickinson and Company (BDX) — Fair Value Analysis
Base-case fair value (P50): $137.61 · Current price: $158.08 · Verdict: Fairly Valued
The Verdict on BDX
Based on our proprietary Monte Carlo simulations, Becton Dickinson (BDX) is currently Fairly Valued. The analysis indicates that BDX's current trading price of $158.08 is closely aligned with its median fair value (P50) of $137.61. This narrow band suggests limited immediate catalysts for significant price movement, with an -12.9% indicating the stock is trading essentially at its computed intrinsic value. For a Healthcare sector company, such alignment often reflects efficient market pricing, especially when considering its operational and financial health is categorized as average. Investors seeking substantial upside potential might find the current valuation less compelling given this tight spread.
How BDX stacks up against Healthcare
BDX's "Fairly Valued" assessment positions it squarely within market expectations for a company of its operational and financial standing in the Healthcare sector. While the sector often presents opportunities for growth, BDX's quality tier is rated as "average." This indicates that while the company maintains a stable footing, its financial metrics and operational efficiency are not significantly outperforming its peers. The Monte Carlo simulations, factoring in this average quality tier, consistently show the $158.08 hovering around $137.61, without a strong probabilistic lean towards either overvaluation or undervaluation. The minimal -12.9% further underscores this balance relative to the broader Healthcare industry dynamics.
What this means for investors
Investors evaluating BDX should note the current equilibrium reflected in the Monte Carlo simulations. With $158.08 trading near $137.61 and an -12.9%, the stock appears to offer limited near-term alpha driven by mispricing. The average quality tier further suggests that BDX is a stable, but not a high-growth, play within the Healthcare sector. While the downside scenario isn't explicitly favored, neither is a strong bull case at this valuation. For those seeking detailed probabilistic outcomes, including bear (P10) and bull (P90) target prices derived from thousands of forward scenarios, FairCurve offers a deeper dive. Sign up for FairCurve to see the full bear/bull distribution and track BDX's fair value as new fundamentals are released.
Frequently Asked Questions
Is BDX overvalued or undervalued right now?
Based on Monte Carlo simulations, Becton Dickinson (BDX) is considered Fairly Valued, with its current price of $158.08 closely matching its median fair value (P50) of $137.61.
What is the bear case and bull case for BDX?
The full Monte Carlo distribution, including bear (P10) and bull (P90) target prices and the probability of upside, is available to users with a free FairCurve account. We do not provide specific dollar values here.
How does FairCurve calculate BDX's fair value?
FairCurve utilizes Monte Carlo simulations, modeling thousands of forward scenarios to determine BDX's intrinsic value, accounting for various fundamental drivers and market conditions.
How can I track BDX's fair value as it changes?
You can add BDX to a free FairCurve watchlist to receive daily fair-value updates and instant re-valuation notifications whenever new earnings or significant fundamental data are released.